Kristin Yarema - 01 Mar 2022 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role: Chief Commercial Officer
Signature: /s/ David Tucker, Attorney-in-Fact for Kristin Yarema
Issuer symbol: ATRA
Transactions as of: 01 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 03 Mar 2022, 18:02:35 UTC
Previous filing: 15 Jun 2021
Next filing: 12 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATRA	Common Stock	Award	$0	+45,533	+36%	$0.000000	171,415	01 Mar 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATRA	Employee Stock Option (Right to Buy)	Award	$0	+85,592		$0.000000	85,592	01 Mar 2022	Common Stock	85,592	$10.21	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year.
F2	1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service.